Search the whole station
Exploring the Mystery of EBV and Tumor 丨Hengsai Biotechnology Shows Its Elegance on the International Academic Stage Again
View details
2024 EHA | Prof. Chunrui Li: Focusing on China's original research power, the field of EBV-associated hematological oncology therapeutics is revitalized
View details
Preface: The dragon is in full bloom, welcome the spring, the elite gathered, the annual event. Looking back to 2023, it is to overcome difficulties and move forward; looking forward to 2024, it is to compete with a hundred boats and oar first. Accompanied by the spring breeze in April, Hengsai Bio held the 2024 Annual Meeting and Spring Tour Group Building Activity in Anji, Zhejiang Province Spring Prelude Annual Feast On April 12, all the staff in a relaxed and happy atmosphere...
View details
China's First! Hengsai Bio's Original DC Vaccine KSD-101 Receives FDA IND Approval
View details
Hengsai Biologicals Completes Tens of Millions of Dollars in Series A+ Financing
View details
Hengsai Bio USA - San Diego The 65th Annual Meeting of the American Society of Hematology (ASH) was grandly held in San Diego, USA on December 9-12, 2023. As the largest, most numerous and most influential annual meeting in the field of international hematology, this year's ASH Congress gathered 35,000 specialists and scholars from 109 countries and regions around the world to present their latest achievements, exchange ...
View details Hengsai Biologicals Completes $100 Million Series A Financing, with MaiPai Capital as Exclusive Financial Advisor
View details
Hengsai Biotechnology
